$SEER

Seer, Inc.

Seer develops proteomics products for researchers at academic institutions, biopharmaceutical companies, biobanks and clinical research organizations. Its Proteograph Product Suite enables large-scale analysis of proteins and includes consumable assays, an automation instrument and data analysis software. The assays use engineered nanoparticles to capture proteins for mass spectrometry analysis, while the software supports quality control, data management and interpretation. Products include the Proteograph ONE and DIRECT assays, the SP200 automation instrument and the Proteograph Analysis Suite. Seer makes money by selling its Proteograph products and services to research customers. The platform supports studies of protein biology, biomarker discovery and integrative research combining proteomic and genomic data. Since its commercial launch in 2021, Seer has served more than 190 customers across over 20 countries. Seer is headquartered in Redwood City, California.

No enriched coverage for $SEER in the last 7 days.

No SEC Form 4 filings for $SEER in the last 30 days.

See all $SEER insider activity →
Med

Seer Q3 2026 slides: scientific gains offset by revenue guidance cut

Seer, Inc. (SEER) reported Q3 2026 revenue of $4.0M, flat YoY but up 29% QoQ. It cut FY2026 revenue guidance to $13.5M-$14.5M from $16M-$18M, citing funding constraints. Shares fell 3.73% in after-hours trading to $1.55. The company highlighted scientific progress but faces commercial growth challenges.

Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced fin

Seer wins ITC staff backing for import ban on Nanomics products

Seer, Inc. (SEER) announced that the U.S. International Trade Commission's staff recommended an import ban on Nanomics' products, alleging patent infringement. The ITC is expected to make a final decision by year-end. Seer also reported recent patent victories in the U.S. and Europe. The company develops proteomics technology and is involved in a related lawsuit against Nanomics.

SEER sentiment & insider activity

Recent SEER coverage spans earnings, mergers & acquisitions and financial news.

What's driving SEER

AlphAI scores every news story that mentions SEER with an AI model for sentiment and relevance, and aggregates insider trades from Seer, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SEER

Score
$SEERMedEarnings

Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced fin

Seer wins ITC staff backing for import ban on Nanomics products

Seer, Inc. (SEER) announced that the U.S. International Trade Commission's staff recommended an import ban on Nanomics' products, alleging patent infringement. The ITC is expected to make a final decision by year-end. Seer also reported recent patent victories in the U.S. and Europe. The company develops proteomics technology and is involved in a related lawsuit against Nanomics.

$SEERLowExec change· resigned

Seer, Inc. (SEER): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Seer, Inc. (SEER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 14, 2026, David Horn resigned as the President, Chief Financial Officer and Treasurer of Seer, Inc. (the “Comp

SEER Looks 5.8% Undervalued on GF Value™

Seer Inc (SEER) shareholders Bradley Radoff and Michael Torok, owning 7.7% of shares, called for board member Meeta Gulyani's resignation, citing her lack of experience and governance engagement. The company's market cap fell over 90% since her appointment. Seer's P/S ratio is 7.92, below its historical median of 9.34, and its GF Score™ is 54/100, indicating mixed fundamentals. Insiders sold shares, while institutional ownership remains stable.

Seer (SEER) Q2 2026 Earnings Call Transcript

Seer (SEER) reported Q2 2026 earnings, highlighting $209.5M in cash reserves and strategic investments, including share repurchases totaling 13.4M shares. The company emphasized scientific validation of its Proteograph Product Suite, with 95 publications supporting its platform. Key studies demonstrated Proteograph's superior performance in proteomics, reinforcing its value proposition and potential for revenue growth. Seer also announced plans to leverage AI for disease detection and highlighte

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.

Related tickers